TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent <i>ex vivo</i> anti-myeloma activity

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2025-11-06
DOI
https://doi.org/10.3324/haematol.2025.288692
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity

Carmay Lim, Junxi Jiang, Tse Wen Chang, Yueh‐Hsiang Yu et al.
Haematologica
Multiple Myeloma Research and Treatments
article

TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity

Carmay Lim, Junxi Jiang, Tse Wen Chang, Yueh‐Hsiang Yu, Shih-Chiang Lin, Hsing‐Mao Chu, Yuan-Bin Yu, S N Cheng
article en

Abstract

No abstract available for this paper.
Haematologica
National Yang Ming Chiao Tung University (TW), ImmuneWorks (United States) (US), Far Eastern Memorial Hospital (TW), ResearchWorks (United States) (US), Universal Trim Supply (Taiwan) (TW), Taipei Medical University (TW), Yuan Ze University (TW)
Openalex Percentile: Top 57%
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.